Aardvark Therapeutics, Inc. 8-K

What Happened
On March 23, 2026, Aardvark Therapeutics, Inc. (AARD) issued a press release reporting its financial results for the quarter and full year ended December 31, 2025, and provided updates on its pipeline and business. The full text of the press release was furnished with the Form 8-K as Exhibit 99.1. The report was signed by Chief Executive Officer Tien‑Li Lee, M.D.

Key Details

• Filing date: March 23, 2026; disclosure reported under Item 2.02 (Results of Operations and Financial Condition).
• Reporting period: quarter and full year ended December 31, 2025.
• Press release containing the detailed results and updates is furnished as Exhibit 99.1 to the Form 8-K.
• Form 8-K was executed by CEO Tien‑Li Lee, M.D.

Why It Matters
The company’s earnings release is the official source for its recent quarterly and full-year revenue, earnings (or loss), and operational updates, along with program/pipeline status that can affect future value. Retail investors should review Exhibit 99.1 (the press release) for the specific financial figures, any guidance or cash/runway information, and milestone news that may influence the stock.